Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma
10.3760/cma.j.issn.0253-2727.2017.09.010
- VernacularTitle: 弥漫大B细胞淋巴瘤患者蛋白表达检测的预后意义
- Author:
Wenjuan YU
1
;
Lihong CAO
;
Jinghan WANG
;
Zhaoming WANG
;
Wenbin QIAN
;
Hongyan TONG
;
Haitao MENG
;
Wenyuan MAI
;
Liping MAO
;
Jiejing QIAN
;
Jie JIN
Author Information
1. The Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou 310003, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, large B cell, diffuse;
Tumor suppressor protein p53;
Proto-oncogene proteins c-myc;
Proto-oncogene proteins c-bcl-2;
Prognosis
- From:
Chinese Journal of Hematology
2017;38(9):784-788
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the prognostic significance of TP53, Bcl-2, Bcl-6, Myc proteins expression by immunohistochemical method (IHC) in diffuse large B cell Lymphoma (DLBCL) .
Methods:Clinical and pathologic data of 223 patients with DLBCL hospitalized in Zhejiang First Hospital from March 2009 to June 2015 were retrospectively analyzed.
Results:The 223 cases, a median age of 56 years old with a male predominance, had shown a 39.0% of TP53 positive expression, 38.6% of Myc, 69.1% of Bcl-2, 56.5% of Bcl-6, and 22.7% of Myc/Bcl-2 double expression. According to Hans’ classification, 27.4% were GCB and 72.6% were non-GCB. With a median follow-up of 38 (2-97) months, the 3 and 5 years survival rates were 70% and 66% , respectively. By multivariate analysis, TP53 over-expression and Myc/Bcl-2 double expression were independently associated with poor outcomes. 3-year and 5-year overall survival were 59% and 57% for patients with TP53 positive, 77% and 71% for patients with TP53 negative expression. Patients with non-GCB subtype receiving chemotherapy combined with rituximab had a higher OS than those without rituximab. But rituximab did not improve the prognosis of patients with TP53 positive.
Conclusion:Myc/Bcl-2 double expression and TP53 over-expression are poor prognosis for DLBCL patients. Patients with Myc/Bcl-2 double expression have shorter OS. Patients with non-GCB subtype who received chemotherapy combined with rituximab have a better OS than those without rituximab. But rituximab does not improve the prognosis of patients with TP53 positive.
